1
|
Yang A, Luo Y, Yang J, Xie T, Wang W, Wan X, Wang K, Pang D, Yang D, Dai H, Wu J, Meng S, Guo J, Wang Z, Shen S. Quantitation of Enterovirus A71 Empty and Full Particles by Sedimentation Velocity Analytical Ultracentrifugation. Viruses 2024; 16:573. [PMID: 38675915 PMCID: PMC11053756 DOI: 10.3390/v16040573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Revised: 04/02/2024] [Accepted: 04/04/2024] [Indexed: 04/28/2024] Open
Abstract
The enterovirus A71 (EV71) inactivated vaccine is an effective intervention to control the spread of the virus and prevent EV71-associated hand, foot, and mouth disease (HFMD). It is widely administered to infants and children in China. The empty particles (EPs) and full particles (FPs) generated during production have different antigenic and immunogenic properties. However, the antigen detection methods currently used were established without considering the differences in antigenicity between EPs and FPs. There is also a lack of other effective analytical methods for detecting the different particle forms, which hinders the consistency between batches of products. In this study, we analyzed the application of sedimentation velocity analytical ultracentrifugation (SV-AUC) in characterizing the EPs and FPs of EV71. Our results showed that the proportions of the two forms could be quantified simultaneously by SV-AUC. We also determined the repeatability and accuracy of this method and found that both parameters were satisfactory. We assessed SV-AUC for bulk vaccine quality control, and our findings indicated that SV-AUC can be used effectively to analyze the percentage of EPs and FPs and monitor the consistency of the process to ensure the quality of the vaccine.
Collapse
Affiliation(s)
- Anna Yang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Yun Luo
- The Research Core Facilities for Life Science (HUST), College of Life Science and Technology, Huazhong University of Science and Technology, Luoyu Road, Wuhan 430074, China
| | - Jie Yang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Tingbo Xie
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Wenhui Wang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Xin Wan
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Kaiwen Wang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Deqin Pang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Dongsheng Yang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Hanyu Dai
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Jie Wu
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Shengli Meng
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Jing Guo
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Zejun Wang
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| | - Shuo Shen
- Wuhan Institute of Biological Products Co., Ltd., No. 1 Huangjin Industrial Park Road, Wuhan 430207, China (J.Y.); (S.M.)
- National Engineering Technology Research Center of Combined Vaccines, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
- Hubei Provincial Vaccines Technology Innozation Center, No. 1 Huangjin Industrial Park Road, Wuhan 430207, China
| |
Collapse
|
3
|
Li ML, Shih SR, Tolbert BS, Brewer G. Enterovirus A71 Vaccines. Vaccines (Basel) 2021; 9:vaccines9030199. [PMID: 33673595 PMCID: PMC7997495 DOI: 10.3390/vaccines9030199] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Revised: 02/22/2021] [Accepted: 02/22/2021] [Indexed: 02/07/2023] Open
Abstract
Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.
Collapse
Affiliation(s)
- Mei-Ling Li
- Department of Biochemistry and Molecular Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA;
- Correspondence:
| | - Shin-Ru Shih
- Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan;
- Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
- Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
- Research Center for Chinese Herbal Medicine, Research Center for Food and Cosmetic Safety, and Graduate Institute of Health Industry Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan
| | - Blanton S. Tolbert
- Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106, USA;
| | - Gary Brewer
- Department of Biochemistry and Molecular Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA;
| |
Collapse
|
4
|
Liu J, Zhao B, Xue L, Wu J, Xu Y, Liu Y, Qin C. Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections. Virol J 2020; 17:58. [PMID: 32321526 PMCID: PMC7178760 DOI: 10.1186/s12985-020-01328-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Accepted: 04/10/2020] [Indexed: 01/25/2023] Open
Abstract
Background Prophylactic vaccines are critical in preventing hand, foot, and mouth disease (HFMD) primarily caused by human enterovirus 71 (EV71) infection. Children aged less than 5 years are especially susceptible to EV71 infections. In addition to the development of vaccines containing the inactivated virus, those containing virus-like particles (VLPs) with repeated antigens also constitute an effective preventive strategy for EV71 infections, with safety and productivity advantages. We previously developed a fusion protein composed with truncated peptides of the EV71 capsid protein, which assembled into spherical particles. This study aimed to assess the immunoprotective effects of this fusion protein as a vaccine candidate in a mouse model of EV71 infection. Methods To evaluate the protective effect of fusion protein vaccine candidate, neonatal mice born by immunized female mice, as well as normal neonatal mice immunized twice were infected with EV71 virus. Whereafter, the survival rates, clinical scores and viral loads were measured. Results The high dosage and booster immunization helped induce specific serum antibodies with high neutralization titers, which were transferred to neonatal mice, thereby facilitating effective resistance towards EV71 infection. An active immune response was also observed in neonatal mice which generated following immunization. Conclusions The present results suggest that this fusion protein is a suitable vaccine candidate in treating EV71 infections.
Collapse
Affiliation(s)
- Jiangning Liu
- NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&PUMC, Beijing, 100021, People's Republic of China
| | - Binbin Zhao
- NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&PUMC, Beijing, 100021, People's Republic of China
| | - Ling Xue
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.,University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of China
| | - Jing Wu
- NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&PUMC, Beijing, 100021, People's Republic of China
| | - Yanfeng Xu
- NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&PUMC, Beijing, 100021, People's Republic of China
| | - Yongdong Liu
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China. .,University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of China.
| | - Chuan Qin
- NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&PUMC, Beijing, 100021, People's Republic of China.
| |
Collapse
|
5
|
Demchuk AM, Patel TR. The biomedical and bioengineering potential of protein nanocompartments. Biotechnol Adv 2020; 41:107547. [PMID: 32294494 DOI: 10.1016/j.biotechadv.2020.107547] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2019] [Revised: 03/21/2020] [Accepted: 04/03/2020] [Indexed: 12/18/2022]
Abstract
Protein nanocompartments (PNCs) are self-assembling biological nanocages that can be harnessed as platforms for a wide range of nanobiotechnology applications. The most widely studied examples of PNCs include virus-like particles, bacterial microcompartments, encapsulin nanocompartments, enzyme-derived nanocages (such as lumazine synthase and the E2 component of the pyruvate dehydrogenase complex), ferritins and ferritin homologues, small heat shock proteins, and vault ribonucleoproteins. Structural PNC shell proteins are stable, biocompatible, and tolerant of both interior and exterior chemical or genetic functionalization for use as vaccines, therapeutic delivery vehicles, medical imaging aids, bioreactors, biological control agents, emulsion stabilizers, or scaffolds for biomimetic materials synthesis. This review provides an overview of the recent biomedical and bioengineering advances achieved with PNCs with a particular focus on recombinant PNC derivatives.
Collapse
Affiliation(s)
- Aubrey M Demchuk
- Department of Neuroscience, University of Lethbridge, 4401 University Drive West, Lethbridge, AB, Canada.
| | - Trushar R Patel
- Alberta RNA Research and Training Institute, Department of Chemistry and Biochemistry, University of Lethbridge, 4401 University Drive West, Lethbridge, AB, Canada; Department of Microbiology, Immunology and Infectious Diseases, Cumming, School of Medicine, University of Calgary, 2500 University Dr. N.W., Calgary, AB T2N 1N4, Canada; Li Ka Shing Institute of Virology and Discovery Lab, Faculty of Medicine & Dentistry, University of Alberta, 6-010 Katz Center for Health Research, Edmonton, AB T6G 2E1, Canada.
| |
Collapse
|
7
|
Zelinkova V, Brazinova A, Taylor MS, Rusnak M, Plancikova D, Melichova J, Majdan M. Location of traumatic brain injury-related deaths: epidemiological analysis of 11 European countries. Brain Inj 2019; 33:830-835. [DOI: 10.1080/02699052.2019.1605622] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Veronika Zelinkova
- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovak Republic
| | - Alexandra Brazinova
- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovak Republic
| | - Mark S Taylor
- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovak Republic
| | - Martin Rusnak
- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovak Republic
| | - Dominika Plancikova
- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovak Republic
| | - Juliana Melichova
- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovak Republic
| | - Marek Majdan
- Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovak Republic
| |
Collapse
|